Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.

about

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

P2860

Q48262294-8C181A27-F4D3-49C1-AAFF-4AFC00046CEE

P2860

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.

Item

http://www.wikidata.org/entity/Q36098713

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.

@ast

Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.

@en

type

Item

label

Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.

@ast

Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.

@en

prefLabel

Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.

@ast

Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.

@en

P1476

Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.

@en

P2093

Giorgi Kvizhinadze

http://www.w3.org/2001/XMLSchema#string

Nisha Nair

http://www.w3.org/2001/XMLSchema#string

William Leung

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab containing regimens for early breast cancer

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

The distinctive nature of HER2-positive breast cancers

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.

Breast cancer in low- and middle-income countries: an emerging and challenging epidemic.

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Cost-effectiveness analysis of breast cancer control interventions in Peru.

P304

e1002067

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PMED.1002067

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tony Blakely

P577

2016-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27504960

http://www.w3.org/2001/XMLSchema#string

P932

4978494

http://www.w3.org/2001/XMLSchema#string

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.

about

P2860

P2860

Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932